Clinical implementation of RNA signatures for pharmacogenomic decision-making

Pharmacogenomics and Personalized Medicine

Volumn 4, Issue 1, 2011, Pages 95-107

  Tang, Weihua ^a   Hu, Zhiyuan ^b   Muallem, Hind ^a   Gulley, Margaret L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Clinical laboratory; Microarray; Preanalytic; Quality assurance; RNA; Translational

Indexed keywords

RNA;

CLINICAL COMPETENCE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CROSS REACTION; DATA ANALYSIS SOFTWARE; DATA MINING; DNA RNA HYBRIDIZATION; GENETIC ALGORITHM; GOOD LABORATORY PRACTICE; GOVERNMENT REGULATION; HUMAN; INFORMATION STORAGE; INTEGRATED HEALTH CARE SYSTEM; LABORATORY DIAGNOSIS; MEDICAL ERROR; MICROARRAY ANALYSIS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROCESS MODEL; REPRODUCIBILITY; REVIEW; RNA ANALYSIS; RNA EXTRACTION; TOTAL QUALITY MANAGEMENT; VALIDATION PROCESS;

EID: 83755173844     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Tumor Analysis Best Practices Working Group. Expression profiling- best practices for data generation and interpretation in clinical trials. Nat Rev Genet. 2004;5(3):229-237.
2. Auer H, Newsom DL, Kornacker K. Expression profiling using Affymetrix GeneChip microarrays. Methods Mol Biol. 2009;509:35-46.
3. Fuscoe JC, Tong W, Shi L. QA/QC issues to aid regulatory acceptance of microarray gene expression data. Environ Mol Mutagen. 2007; 48(5):349-353.
4. Hackett JL, Gutman SI. Introduction to the Food and Drug Administration (FDA) regulatory process. J Proteome Res. 2005;4(4):1110-1113.
5. Imbeaud S, Auffray C. The '39 steps' in gene expression profiling: Critical issues and proposed best practices for microarray experiments. Drug Discov Today. 2005;10(17):1175-1182.
6. National Cancer Institute. NCI Best Practices for Biospecimen Resources. Bethesda, MD: United States National Cancer Institute; 2010. Available from: http://www.allirelandnci.com/pdf/NCI_Best_Practices_060507.pdf. Accessed August 18, 2011.
7. Fox P, Hendler J. Changing the equation on scientific data visualization. Science. 2011;331(6018):705-708.
8. Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-755.
9. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev. 2010;23(3):550-576.
10. Kohl M. Development and validation of predictive molecular signatures. Curr Mol Med. 2010;10(2):173-179.
11. Archer KJ, Mas VR, O'Brien TR, Pfeiffer R, Lum NL, Fisher RA. Quality assessment of microarray data in a multicenter study. Diagn Mol Pathol. 2009;18(1):34-43.
12. Bammler T, Beyer RP, Bhattacharya S, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005;2(5):351-356.
13. Coyle VM, Johnston PG. Genomic markers for decision making: What is preventing us from using markers? Nat Rev Clin Oncol. 2010;7(2):90-97.
14. Shack S. Gene expression profiling of tissues and cell lines: A dual-color microarray method. Methods Mol Biol. 2011;700:125-143.
15. Oberthuer A, Juraeva D, Li L, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J. 2010; 10(4):258-266.
16. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol. 2006; 24(9):1140-1150.
17. Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat Res. 2003;543(3):217-234.
18. de Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009;9:409.
19. Lippi G, Chance JJ, Church S, et al. Preanalytical quality improvement: From dream to reality. Clin Chem Lab Med. 2011;49(7):1113-1126.
20. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44(6):750-759.
21. Schmitt M, Mengele K, Schueren E, et al. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur J Cancer. 2007;43(5):835-844.
22. Drubin D, Smith JS, Liu W, Zhao W, Chase GA, Clawson GA. Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens. Breast Cancer Res Treat. 2005;90(1):93-96.
23. Jochumsen KM, Tan Q, Dahlgaard J, Kruse TA, Mogensen O. RNA quality and gene expression analysis of ovarian tumor tissue undergoing repeated thaw-freezing. Exp Mol Pathol. 2007;82(1):95-102.
24. Vartanian K, Slottke R, Johnstone T, et al. Gene expression profiling of whole blood: Comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics. 2009;10(1):2.
25. Rainen L, Arbique JC, Asthana D, et al. Clinical Laboratory Standards Institute Document MM13-A: Collection, transport, preparation, and storage of specimens for molecular methods approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
26. Leyland-Jones BR, Ambrosone CB, Bartlett J, et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol. 2008;26(34):5638-5644.
27. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen Reporting for Improved Study Quality (BRISQ). J Proteome Res. 2011;10(8): 3429-3438.
28. Williams MA. Stabilizing the code-methods to preserve RNA prove their worth. Biomark Insights. 2010;5:139-143.
29. Asare AL, Kolchinsky SA, Gao Z, et al. Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genomics. 2008;9:474.
30. Matheson LA, Duong TT, Rosenberg AM, Yeung RS. Assessment of sample collection and storage methods for multicenter immunologic research in children. J Immunol Methods. 2008;339(1):82-89.
31. Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics. 2006;87(5):653-664.
32. Shou J, Dotson C, Qian HR, et al. Optimized blood cell profiling method for genomic biomarker discovery using high-density microarray. Biomarkers. 2005;10(4):310-320.
33. Weber DG, Casjens S, Rozynek P, et al. Assessment of mRNA and microRNA stabilization in peripheral human blood for multicenter studies and biobanks. Biomark Insights. 2010;5:95-102.
34. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132(12):1929-1935.
35. Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM, Rubin MA. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol. 2002;161(5): 1743-1748.
36. Ferruelo A, El-Assar M, Lorente JA, et al. Transcriptional profiling and genotyping of degraded nucleic acids from autopsy tissue samples after prolonged formalin fixation times. Int J Clin Exp Pathol. 2011;4(2):156-161.
37. Roepman P, de Koning E, van Leenen D, et al. Dissection of a metastatic gene expression signature into distinct components. Genome Biol. 2006;7(12):R117.
38. Macabeo-Ong M, Ginzinger DG, Dekker N, et al. Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. Mod Pathol. 2002;15(9):979-987.
39. Chung JY, Hewitt SM. An optimized RNA extraction method from archival formalin-fixed paraffin-embedded tissue. Methods Mol Biol. 2010;611:19-27.
40. Budczies J, Weichert W, Noske A, et al. Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays. J Histochem Cytochem. 2011;59(2): 146-157.
41. Saleh A, Zain RB, Hussaini H, et al. Transcriptional profiling of oral squamous cell carcinoma using formalin-fixed paraffin-embedded samples. Oral Oncol. 2010;46(5):379-386.
42. Ton CC, Vartanian N, Chai X, et al. Gene expression array testing of FFPE archival breast tumor samples: An optimized protocol for WG-DASL sample preparation. Breast Cancer Res Treat. 2011; 125(3):879-883.
43. Chung JY, Braunschweig T, Williams R, et al. Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffinembedded tissue. J Histochem Cytochem. 2008;56(11):1033-1042.
44. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
45. Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by Affymetrix microarrays. J Mol Diagn. 2010;12(4):409-417.
46. Duenwald S, Zhou M, Wang Y, et al. Development of a microarray platform for FFPET profiling: Application to the classification of human tumors. J Transl Med. 2009;7:65.
47. Mittempergher L, de Ronde JJ, Nieuwland M, et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One. 2011;6(2):e17163.
48. Roberts L, Bowers J, Sensinger K, Lisowski A, Getts R, Anderson MG. Identification of methods for use of formalin-fixed, paraffin-embedded tissue samples in RNA expression profiling. Genomics. 2009;94(5): 341-348.
49. Cox ML, Schray CL, Luster CN, et al. Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol. 2006;80(2):183-191.
50. Cox ML, Eddy SM, Stewart ZS, et al. Investigating fixative-induced changes in RNA quality and utility by microarray analysis. Exp Mol Pathol. 2008;84(2):156-172.
51. Lawson MH, Rassl DM, Cummings NM, et al. Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol. 2010;5(7):956-963.
52. Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC. Tissue handling for genome-wide expression analysis: A review of the issues, evidence, and opportunities. Arch Pathol Lab Med. 2007; 131(12):1805-1816.
53. Hess C, Denkers F, Ossenkoppele G, et al. Gene expression prof iling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia. 2004;18(12): 1981-1988.
54. Wang S, Wang L, Zhu T, et al. Improvement of tissue preparation for laser capture microdissection: Application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics. 2010;11:163.
55. Luttges J, Hahn SA, Heidenblut AM. Manual microdissection combined with antisense RNA-longSAGE for the analysis of limited cell numbers. Methods Mol Biol. 2010;576:135-154.
56. Mojica WD, Sykes DE, Conroy J, Gaile D, Fang X, Nowak N. A comparative analysis of two tissue procurement approaches for the genomic profiling of clinical colorectal cancer samples. Int J Colorectal Dis. 2008;23(11):1089-1098.
57. Mojica WD, Stein L, Hawthorn L. Universal Reference RNA is not a representative normal sample for oligonucleotide microarray studies. Pathol Oncol Res. 2008;14(3):243-51.
58. Mojica WD, Stein L, Hawthorn L. An exfoliation and enrichment strategy results in improved transcriptional profiles when compared to matched formalin fixed samples. BMC Clin Pathol. 2007;7:7.
59. Burgemeister R. Nucleic acids extraction from laser microdissected FFPE tissue sections. Methods Mol Biol. 2011;724:117-129.
60. Shi L, Perkins RG, Fang H, Tong W. Reproducible and reliable microarray results through quality control: Good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol. 2008;19(1):10-18.
61. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24(9): 1151-1161.
62. Novoradovskaya N, Whitfield ML, Basehore LS, et al. Universal reference RNA as a standard for microarray experiments. BMC Genomics. 2004;5(1):20.
63. Auer H, Lyianarachchi S, Newsom D, Klisovic MI, Marcucci G, Kornacker K. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat Genet. 2003;35(4):292-293.
64. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
65. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8(2):R19.
66. Becker C, Hammerle-Fickinger A, Riedmaier I, Pfaffl MW. MRNA and microRNA quality control for RT-qPCR analysis. Methods. 2010;50(4):237-243.
67. Devonshire AS, Elaswarapu R, Foy CA. Evaluation of external RNA controls for the standardisation of gene expression biomarker measurements. BMC Genomics. 2010;11:662.
68. Baker SC, Bauer SR, Beyer RP, et al. The external RNA controls consortium: A progress report. Nat Methods. 2005;2(10):731-734.
69. Invitrogen. Available from: www.invitrogen.com. Accessed May 7, 2011.
70. VWR International. Available from: https://ca.vwr.com. Accessed August 25, 2011.
71. Fan X, Fang H, Hong H, Perkins R, Shi L, Tong W. Correlation analysis of external RNA controls reveals its utility for assessment of microarray assay. Anal Biochem. 2009;385(2):203-207.
72. Walter M, Honegger A, Schweizer R, Poths S, Bonin M. Utilization of AFFX spike-in control probes to monitor sample identity throughout Affymetrix GeneChip Array processing. Biotechniques. 2010; 48(5):371-378.
73. Staal FJ, Cario G, Cazzaniga G, et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia. 2006;20(8):1385-1392.
74. Rudloff U, Bhanot U, Gerald W, et al. Biobanking of human pancreas cancer tissue: Impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol. 2010;17(8):2229-2236.
75. Botling J, Micke P. Biobanking of fresh frozen tissue from clinical surgical specimens: Transport logistics, sample selection, and histologic characterization. Methods Mol Biol. 2011;675:299-306.
76. Botling J, Micke P. Fresh frozen tissue: RNA extraction and quality control. Methods Mol Biol. 2011;675:405-413.
77. Botling J, Edlund K, Segersten U, et al. Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol. 2009;18(1):44-52.
78. Vermeulen J, Derveaux S, Lefever S, et al. RNA pre-amplification enables large-scale RT-qPCR gene-expression studies on limiting sample amounts. BMC Res Notes. 2009;2:235.
79. Gonzalez-Roca E, Garcia-Albeniz X, Rodriguez-Mulero S, Gomis RR, Kornacker K, Auer H. Accurate expression profiling of very small cell populations. PLoS One. 2010;5(12):e14418.
80. Corbi FC, Inaoka RJ, Felix RS, et al. Comparative expression of a set of genes to an internal housekeeping control in CDNA amplified and not amplified by PolyAPCR in non-Hodgkin's lymphoma samples obtained from fine-needle aspiration cytology. Diagn Mol Pathol. 2010;19(1):40-44.
81. Ferreira EN, Maschietto M, Silva SD, Brentani H, Carraro DM. Evaluation of quantitative rt-PCR using nonamplified and amplified RNA. Diagn Mol Pathol. 2010;19(1):45-53.
82. Spurgeon SL, Jones RC, Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One. 2008;3(2):e1662.
83. Glaves PD, Tugwood JD. Generation and analysis of transcriptomics data. Methods Mol Biol. 2011;691:167-185.
84. Lippa KA, Duewer DL, Salit ML, Game L, Causton HC. Exploring the use of internal and external controls for assessing microarray technical performance. BMC Res Notes. 2010;3:349.
85. Feng L, Liu H, Liu Y, et al. Power of deep sequencing and agilent microarray for gene expression profiling study. Mol Biotechnol. 2010;45(2):101-110.
86. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006;24(9):1115-1122.
87. Coppée JY. Do DNA microarrays have their future behind them? Microbes Infect. 2008;10(9):1067-1071.
88. Anonymous. Quality System (QS) Regulation/Medical Device Good Manufacturing Practices. Silver Spring, MD: Food and Drug Administration; 2011. Available from: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations. Accessed May 7, 2011.
89. International Organization for Standardization. ISO 900 Essentials. Geneva, Switzerland. Available from: www.iso.org/iso/iso_9000_essentials. Accessed May 7, 2011.
90. Bengtsson M, Ståhlberg A, Rorsman P, Kubista M. Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels. Genome Res. 2005;15(10):1388-1392.
91. Ritchie ME, Silver J, Oshlack A, et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007;23(20):2700-2707.
92. Durbin BP, Rocke DM. Variance-stabilizing transformations for twocolor microarrays. Bioinformatics. 2004;20(5):660-667.
93. Fan J, Niu Y. Selection and validation of normalization methods for c-DNA microarrays using within-array replications. Bioinformatics. 2007;23(18):2391-2398.
94. McMullen PD, Morimoto RI, Amaral LAN. Physically grounded approach for estimating gene expression from microarray data. Proc Natl Acad Sci U S A. 2010;107(31):13690-13695.
95. Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28(8):827-838.
96. Hackett JL, Archer JK, Gaigalas AK, et al. Clinical and Laboratory Standards Institute Document MM12-A: Diagnostic nucleic acid microarrays approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2006. Available from: http://www.clsi.org/source/orders/free/mm12AF.pdf. Accessed August 18, 2011.
97. Hubble J, Demeter J, Jin H, et al. Implementation of GenePattern within the Stanford Microarray Database. Nucleic Acids Res. 2009;37(Database issue):D898-D901.
98. Simon R. Analysis of DNA microarray expression data. Best Pract Res Clin Haematol. 2009;22(2):271-282.
99. Parry RM, Jones W, Stokes TH, et al. k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. Pharmacogenomics J. 2010;10(4):292-309.
100. Monzon FA, Medeiros F, Lyons-Weiler M, Henner WD. Identification of tissue of origin in carcinoma of unknown primary with a microarraybased gene expression test. Diagn Pathol. 2010;5:3.
101. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol. 2009;27(31):5175-5181.
102. Izraeli S. Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: From bench to bedside? Br J Haematol. 2010;151(2):119-131.
103. Jelier R, Goeman JJ, Hettne KM, Schuemie MJ, den Dunnen JT, T'Hoen PA. Literature-aided interpretation of gene expression data with the weighted global test. Brief Bioinform. February 9, 2011. [Epub ahead of print.]
104. Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid ACCE: Experience with a rapid and structured approach for evaluating genebased testing. Genet Med. 2007;9(7):473-478.
105. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131(6):852-863.
106. Schiff GD, Hasan O, Kim S, et al. Diagnostic error in medicine: Analysis of 583 physician-reported errors. Arch Intern Med. 2009;169(20):1881-1887.
107. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer. 2007;7(7):545-553.
108. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med. 2009;11(1):66-73.
109. Mook S, Bonnefoi H, Pruneri G, et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling: Logistics pilot study preceding the MINDACT trial. Eur J Cancer. 2009;45(7):1201-1208.
110. National Comprehensive Cancer Network. NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 2.2011). 2011. Available from: www.nccn.org. Accessed June 7, 2011.
111. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5212.
112. National Comprehensive Cancer Network. NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2011). Available from: www.nccn.org. Accessed June 7, 2011.
113. Rivers PA, Dobalian A, Germinario FA. A review and analysis of the clinical laboratory improvement amendment of 1988: Compliance plans and enforcement policy. Health Care Manage Rev. 2005;30(2):93-102.
114. United States Food and Drug Administration. United States Food and Drug Administration MicroArray Quality Control (MAQC) project. Available from: http://www.fda.gov/ScienceResearch/BioinformaticsTools/MicroarrayQualityControlProject/default.htm. Accessed June 7, 2011.
115. Fan X, Lobenhofer EK, Chen M, et al. Consistency of predictive signature genes and classifiers generated using different microarray platforms. Pharmacogenomics J. 2010;10(4):247-257.
116. Shi W, Bessarabova M, Dosymbekov D, et al. Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogenomics J. 2010;10(4):310-323.
117. Tillinghast GW. Microarrays in the clinic. Nat Biotechnol. 2010;28(8): 810-812.
118. Bustin SA, Beaulieu JF, Huggett J, et al. MIQE precis: Practical implementation of minimum standard guidelines for fluorescencebased quantitative real-time PCR experiments. BMC Mol Biol. 2010;11:74.
119. College of American Pathologists. Available from: www.cap.org. Accessed May 7, 2011.
120. Warrington JA, Corbisier P, Feilotter H, et al. Clinical Laboratory Standards Institute Document MM16-A: Use of external RNA controls in gene expression assays approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
121. Wilson JA, Zoccoli MA, Jacobson JW, et al. Clinical Laboratory Standards Institute Document MM17-A: Verification and validation of multiplex nucleic acid assays approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
122. Valdes R, Payne D, Linder MW, et al. Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington, DC: National Academy of Clinical Biochemistry; 2007.
123. Szecsi PB, Odum L. Error tracking in a clinical biochemistry laboratory. Clin Chem Lab Med. 2009;47(10):1253-1257.
124. Fabbretti G. Risk management: Correct patient and specimen identification in a surgical pathology laboratory. The experience of Infermi Hospital, Rimini, Italy. Pathologica. 2010;102(3):96-101.
125. Valenstein PN, Alpern GA, Keren DF. Responding to large-scale testing errors. Am J Clin Pathol. 2010;133(3):440-446.
126. Staines H, Garcia-Fernandez L, Pogothata R, Wallace P, MacKay W, van Loon A. Monitoring performance of nucleic acid-based diagnostic measurement system users by EQA. Accreditation and Quality Assurance: Journal for Quality, Comparability and Reliability in Chemical Measurement. 2009;14(5):243-252.
127. Tholen DW BL, Boone DJ, Cooper WG, et al. Clinical Laboratory Standards Institute document GP27-A2: Using proficiency testing to improve the clinical laboratory approved guideline. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
128. Madej RM, Cao Z, Dolinger DL, Hall L, Neuwald P, Williams LO. Clinical and Laboratory Standards Institute Document MM14-A: Proficiency testing (external quality assessment) for molecular methods approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
129. Quality Control for Molecular Diagnostics. Available from: www.qcmd.org. Accessed May 7, 2011.
130. Sarewitz SJ, George H, Miller WG, Tholen DW, Valenstein PN. Clinical Laboratory Standards Institute Document GP29-A2: Assessment of laboratory tests when proficiency testing is not available approved guideline. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
131. Association for Molecular Pathology. AMP Test Directory. Available from: www.amptestdirectory.org. Accessed May 7, 2011.
132. National Center for Biotechnology Information. Gene Tests. Available from: www.genetests.org. Accessed May 7, 2011.
133. Bild AH, Parker JS, Gustafson AM, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009;11(4):R55.
134. Hu Z, Fan C, Livasy C, et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009;7:9.
135. Huang J, Shi W, Zhang J, et al. Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J. 2010;10(4): 267-277.